Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH for Richter’s syndrome.
Read here:Â https://meetinglibrary.asco.org/record/186876/abstract
Matthew Davids, MD on Phase II Study of Venetoclax: Standard of Care @DanaFarber
